Lupin gets USFDA’s nod for Pirfenidone Tablets

25 Aug 2023 Evaluate

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Pirfenidone Tablets, 267 mg and 801 mg, to market a generic equivalent of Esbriet Tablets, 267 mg and 801 mg of Hoffmann La Roche Inc. This product will be manufactured at Lupin’s Pithampur facility in India.

Pirfenidone Tablets (RLD Esbriet) had estimated annual sales of $218 million in the U.S. (IQVIA MAT June 2023).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2120.00 -1.65 (-0.08%)
29-Jan-2026 13:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1597.90
Dr. Reddys Lab 1200.00
Cipla 1319.40
Zydus Lifesciences 887.50
Lupin 2120.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×